BCYC - Bicycle Therapeutics: Novel Bicycle Peptide Technology Could Disrupt The Monoclonal Antibodies Market
Bicycle Therapeutics (BCYC) (“the company”) was founded in 2009 and is based in Cambridge, the UK, and Cambridge, Massachusetts.
What are Bicycle peptides:
Bicycle peptides are fully synthetic short peptides constrained to form two loops using a chemical connector compound known as a scaffold, which stabilizes their structural geometry. The company uses a proprietary phage display screening platform for the cyclization of linear peptides and their screening. The science behind bicycle peptides originated in the labs of the company’s co-founder Greg Winter, 2018 Nobel Prize winner British biochemist who is known for his work on